Drugs Stocks On The Rise With Help From 5 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 56 points (-0.3%) at 15,939 as of Wednesday, Feb. 12, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,598 issues advancing vs. 1,323 declining with 154 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Seattle Genetics ( SGEN), up 11.4%, Incyte ( INCY), up 4.3%, Jazz Pharmaceuticals ( JAZZ), up 4.5%, Biomarin Pharmaceutical ( BMRN), up 3.4% and GlaxoSmithKline ( GSK), up 1.1%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 1.4%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.70 (1.1%) to $66.16 on light volume. Thus far, 590,003 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $65.92-$66.42 after having opened the day at $65.92 as compared to the previous trading day's close of $65.46.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $81.0 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate AstraZeneca a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Allergan ( AGN) is up $0.72 (0.6%) to $123.44 on average volume. Thus far, 1.3 million shares of Allergan exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $122.63-$124.93 after having opened the day at $122.64 as compared to the previous trading day's close of $122.71.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $36.5 billion and is part of the health care sector. Shares are up 10.5% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.47 (0.9%) to $53.09 on light volume. Thus far, 2.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $52.54-$53.33 after having opened the day at $52.62 as compared to the previous trading day's close of $52.62.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $85.8 billion and is part of the health care sector. Shares are down 1.0% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is up $1.55 (0.5%) to $321.37 on average volume. Thus far, 562,481 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $318.63-$324.89 after having opened the day at $319.27 as compared to the previous trading day's close of $319.82.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $75.2 billion and is part of the health care sector. Shares are up 14.4% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $1.41 (0.9%) to $161.32 on average volume. Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $160.40-$163.14 after having opened the day at $160.50 as compared to the previous trading day's close of $159.91.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $64.5 billion and is part of the health care sector. Shares are down 5.4% year-to-date as of the close of trading on Tuesday. Currently there are 24 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

AstraZeneca Stock Gains as Crestor Sales Decline Slows

AstraZeneca Stock Gains as Crestor Sales Decline Slows

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug